Oxford Biomedica PLC Director Dealings / Market Share Sale and Purchase (6631O)
August 22 2017 - 4:35AM
UK Regulatory
TIDMOXB
RNS Number : 6631O
Oxford Biomedica PLC
22 August 2017
Director Dealings / Market Share Sale and Purchase
Oxford, UK - 22 August 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), a leading gene and cell
therapy group, was informed that on 21 August 2017 Tim Watts, Chief
Financial Officer, exercised options over 8,244,169 ordinary shares
of 1p each ("Ordinary Shares") in the Company. The options were
exercisable at a cost of 1p per share and Mr Watts has sold 965,374
shares at 8.6p in order to fund the GBP82,442 cost of exercise.
These options were granted in 2012, 2013 and 2014 under the
Company's 2007 Long Term Incentive Plan.
Following the exercise Mr Watts holds 15,998,954 ordinary shares
of 1p each ("Ordinary Shares") in the Company, 0.52% of the
Company's issued share capital.
The issued share capital of the Company is 3,103,516,399 1p
ordinary shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
280 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPTMLTMBJTMJR
(END) Dow Jones Newswires
August 22, 2017 05:35 ET (09:35 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024